Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Amicus Therapeutics Q1 Adj. EPS $0.03 Beats $(0.05) Estimate, Sales $125.20M Miss $135.86M Estimate

Author: Benzinga Newsdesk | May 01, 2025 06:10am
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.05) by 160 percent. This is a 250 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $125.20 million which missed the analyst consensus estimate of $135.86 million by 7.85 percent. This is a 13.40 percent increase over sales of $110.40 million the same period last year.

Posted In: FOLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist